NEXT&BIO’s expansion of its R&D operations in Singapore will deepen its collaboration with the Cancer Science Institute of Singapore (CSI Singapore), building on the agreement established in August 2025.

The collaboration focuses on developing patient-derived cancer models that reflect Singapore’s diverse Asian population, supporting drug development and treatment-response research.

Read the official press release:
https://lnkd.in/gS9mEurT